Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMAP), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation’s 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) is backed by an issuer that regularly releases detailed updates on its royalty portfolio, corporate transactions, and preferred stock dividends. This news page aggregates coverage related to XOMAP through the lens of XOMA Royalty’s broader business activities as a biotechnology royalty aggregator.
Company press releases frequently describe new royalty and milestone acquisitions, amendments to existing collaborations, and completed takeovers of biotechnology firms. Examples include transactions involving Turnstone Biologics, HilleVax, LAVA Therapeutics, and Mural Oncology, as well as an amended royalty-sharing arrangement with Takeda related to mezagitamab and a basket of additional development-stage assets. These announcements provide context on how XOMA Royalty is expanding and diversifying the economic interests that underpin its capital structure, including its preferred shares.
Investors following XOMAP can also find recurring announcements of quarterly cash dividends authorized for holders of the Series A preferred stock, along with similar disclosures for the Series B preferred depositary shares. Financial result releases outline royalty and milestone receipts from commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, as well as updates on investigational compounds in the company’s milestone and royalty portfolio.
By reviewing the news associated with XOMAP and its issuer, readers can track developments in XOMA Royalty’s acquisition activity, portfolio composition, and preferred stock dividend practices. This page can be a useful reference for monitoring how new deals, partner progress, and capital allocation decisions may relate to the preferred securities over time.
XOMA Royalty reported Q3 2024 financial results with total income of $7.2 million, including $6.5 million from commercial products. Cash receipts totaled $9.9 million in Q3 and $42.3 million for the first nine months of 2024. The company recorded a net loss of $17.2 million, primarily due to a $14.0 million non-cash impairment related to Agenus. Notable events include FDA approval of MIPLYFFA™ for Niemann-Pick disease Type C and acquisition of 50% economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets. Cash position stood at $146.8 million as of September 30, 2024.
XOMA Royalty announced that Zevra Therapeutics has received FDA approval for MIPLYFFA™ (arimoclomol), the first therapy approved for use in patients with Niemann-Pick Disease Type C (NPC). MIPLYFFA™ is approved for use in combination with miglustat to treat neurological manifestations of NPC in patients two years and older.
XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones. This approval marks MIPLYFFA™ as the sixth commercial asset in XOMA Royalty's portfolio. In June 2023, XOMA Royalty acquired these rights from LadRx for a $5 million upfront payment plus a share of future event-based milestones.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share. Holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per depositary share. The dividends will be paid on or about October 15, 2024, to holders of record as of the close of business on October 3, 2024. This announcement demonstrates XOMA's commitment to providing returns to its preferred stockholders.
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in two major investor conferences in September 2024. The company's executive team, including CEO Owen Hughes and CIO Brad Sitko, will present corporate overviews at:
1. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024). Presentation scheduled for September 9 at 9:00 AM ET.
2. The 2024 Cantor Global Healthcare Conference in New York, NY (September 17-19, 2024). Presentation scheduled for September 17 at 2:30 PM ET.
Both presentations will be accessible via provided links and through XOMA's investor relations website. Replays will be available for 90 days after each event.
XOMA Royalty (NASDAQ: XOMA) reported its second quarter 2024 financial results and highlighted recent activities. Key points include:
- Cash receipts totaled $22.6 million in Q2 2024, including royalty income and milestones
- Expanded commercial royalty portfolio with acquisition of interests in XACIATO™ and two Phase 3 assets
- Completed acquisition of Kinnate Pharmaceuticals, adding potential royalty streams and over $9.5 million in capital
- FDA approved Day One's OJEMDA™, becoming XOMA's fifth commercial royalty
- Recorded total income and revenues of $11.1 million for Q2 2024
- Reported net income of $16.0 million for Q2 2024, compared to a net loss of $5.4 million in Q2 2023
- Cash and cash equivalents of $149.9 million as of June 30, 2024
XOMA (Nasdaq: XOMA) has announced that its Board of Directors has approved quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock.
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a dividend of $0.53906 per share. Holders of depositary shares representing 1/1000 of a share of the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will get a dividend of $0.52344 per depositary share.
These dividends are scheduled to be paid on or about July 15, 2024, to shareholders of record as of July 3, 2024.
XOMA (NASDAQ: XOMA) announced an $8.1 million milestone payment from Viracta Therapeutics. This is linked to Day One Biopharmaceuticals' sale of its Priority Review Voucher (PRV) for $108 million. OJEMDA™, the only approved therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), has contributed to this milestone. XOMA's CEO, Owen Hughes, highlighted that the milestone has more than covered their initial $13.5 million investment made in March 2021. They expect future royalties from OJEMDA™ to enhance their royalty portfolio and generate sustainable cash flow.
XOMA , a biotech royalty aggregator listed on NASDAQ under the symbol 'XOMA', announced its participation in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference. The event will take place at NASDAQ in New York on May 20, 2024.
CEO Owen Hughes and CIO Brad Sitko will represent XOMA in a fireside chat scheduled for 11:00 AM ET. The presentation can be accessed online via a provided link, and replays will be available on XOMA's investor relations website for 90 days post-event.
XOMA reported its first quarter 2024 financial results, earning a $9 million milestone with the FDA approval of OJEMDA™, gaining $9.5 million from Kinnate acquisition, expanding its portfolio, and initiating a $50 million stock repurchase program. The company also reported $1.5 million in total revenues for Q1 2024.
XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMAP)?
